| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
GAITHERSBURG, Md.—Gene therapy specialist VIRxSYS announced it had acquired all core technology and preclinical programs of Intronn, Inc., including the spliceosome-mediated RNA trans-splicing technology (SMaRT), which seeks to repair gene function, not silence it. Financial details were not disclosed, but deal was an all-stock transaction.
 
"This is a major step in our company's capabilities and growth," says Dr. Riku Rautsola, VIRxSYS president and CEO.  "Adding the SMaRT RNA platform to our lentiviral vector delivery platform will help us build VIRxSYS into the driving force behind the next generation of gene therapy."
 
The move puts VIRxSYS firmly in an already crowded RNA-based technologies marketplace that according to a 2006 report by Frost & Sullivan, is expected to reach almost $300 million by 2012 in the United States alone. What will set VIRxSYS apart from the field will be the company's move away from the RNAi pack. Only time will tell if this was a smart move.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue